Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study - Meric-Bernstam, F; Hurwitz, H; Raghav, KPS (Lancet Oncol, 2019)